Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinisches Magazin
Erschienen in:

01.04.2013 | Originalarbeit

Aktuelles aus der Mykologie

Zunehmende Resistenzentwicklung von Hefe- und Schimmelpilzen

verfasst von: Dr. B. Risslegger, Univ.-Prof. Dr. C. Lass-Flörl

Erschienen in: Wiener klinisches Magazin | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Auszug

Die Inzidenz von invasiven Pilzinfektionen hat in den vergangenen 30 Jahren aufgrund der steigenden Anzahl von organtransplantierten Patienten, neuen onkologischen Therapiemöglichkeiten und AIDS-Patienten zugenommen [1, 2, 3, 4]. Für die Therapie stehen im Wesentlichen 3 Substanzklassen zur Verfügung: Polyene (konventionelles Amphotericin B und Lipidpräparationen), Azole (Fluconazol, Voriconazol, Posaconazol, Itraconazol) und Echinocandine (Caspofungin, Anidulafungin, Micafungin). …
Vorheriger Artikel kurz & bündig
Nächster Artikel aktuell leber
Literatur
1.
Pfaller MA, Diekema DJ (2004) Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42(10):4419–4431PubMedCrossRef
2.
Pfaller MA, Diekema DJ (2004) Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 10(Suppl 1):11–23PubMedCrossRef
3.
Walsh TJ, Groll A, Hiemenz J et al (2004) Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 10(Suppl 1):48–66PubMedCrossRef
4.
Kontoyiannis DP, Lewis RE (2002) Antifungal drug resistance of pathogenic fungi. Lancet 359:1135–1144PubMedCrossRef
5.
Hadrich I, Makni F, Neji S et al (2012) Invasive aspergillosis: resistance to antifungal drugs. Mycopathologia 174(2):131–141PubMedCrossRef
6.
Kanafani ZA, Perfect JR (2008) Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 46:120–128PubMedCrossRef
7.
Andes D (2006) Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 20:679–697PubMedCrossRef
8.
Shakeri-Nejad K, Stahlmann R (2006) Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 7:639–651PubMedCrossRef
9.
Mora-Duarte J, Betts R, Rotstein C et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020–2029PubMedCrossRef
10.
Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415PubMedCrossRef
11.
Pfaller MA (2012) Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 125(1 Suppl):S3–S13PubMedCrossRef
12.
Agvald-Ohman C, Klingspor L, Hjelmqvist H, Edlund C (2007) Invasive candidiasis in long-term patients at a multidisciplinary intensive care unit: Candida colonization index, risk factors, treatment and outcome. Scand J Infect Dis 40:1–9
13.
Charles PE, Dalle F, Aube H et al (2005) Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med 31:393–400PubMedCrossRef
14.
Leon C, Ruiz-Santana S, Saavedra P et al (2006) A bedside scoring system (‚‚Candida score’‘) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34:730–737PubMedCrossRef
15.
Lass-Flörl C (2009) The changing face of epidemiology of invasive fungal disease in Europe. Mycosis 52:197–205CrossRef
16.
Tortorano AM, Kibbler C, Peman J et al (2006) Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 27:359–366PubMedCrossRef
17.
Jorda-Marcos R, Alvarez-Lerma F, Jurado M et al (2007) Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses 50:302–310PubMedCrossRef
18.
Eggimann P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3:685–702PubMedCrossRef
19.
Almirante B, Rodriguez D, Park BJ et al (2005) Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43:1829–1835PubMedCrossRef
20.
Walraven CJ, Lee SA (2012) Antifungal lock therapy. Antimicrob Agents Chemother (Epub 15 Oct 2012)
21.
Hidron AI, Edwards JR, Patel J et al (2008) NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29(11):996–1011PubMedCrossRef
22.
Wisplinghoff H, Bischoff T, Tallent SM et al (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309–317PubMedCrossRef
23.
Trick WE, Fridkin SK, Edwards JR et al (2002) Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 35(5):627–630PubMedCrossRef
24.
Pappas PG, Rex JH, Lee J et al (2003) A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37(5):634–643PubMedCrossRef
25.
Marr KA (2004) Invasive Candida infections: the changing epidemiology. Oncology (Williston Park) 18(14 Suppl 13):9–14
26.
Pappas PG, Rex JH, Sobel JD et al (2004) Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 38(2):161–189PubMedCrossRef
27.
28.
De Luca C, Guglielminetti M, Ferrario A et al (2012) Candidemia: species involved, virulence factors and antimycotic susceptibility. New Microbiol 35(4):459–468
29.
Morace G, Borghi E (2010) Fungal infections in ICU patients: epidemiology and the role of diagnostics. Minerva Anestesiol 76(11):950–956PubMed
30.
Clark TA, Slavinski SA, Morgan J et al (2004) Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol 42:4468–4472PubMedCrossRef
31.
Komshian SV, Uwaydah AK, Sobel JD, Crane LR (1989) Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 11:379–390PubMedCrossRef
32.
Lin MY, Carmeli Y, Zumsteg J et al (2005) Prior antimicrobial therapy and risk for hospital acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 49:4555–4560PubMedCrossRef
33.
Bassetti M, Ansaldi F, Nicolini L et al (2009) Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother 64:625–629PubMedCrossRef
34.
Bassetti M, Taramasso L, Nicco E et al (2011) Epidemology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 6(9):e24198PubMedCrossRef
35.
Rocco TR, Reinsert SE, Simms HH (2000) Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg 135:160–165PubMedCrossRef
36.
37.
Alem MA, Douglas LJ (2005) Prostaglandin production during growth of Candida albicans biofilms. J Med Microbiol 54:1001–1005PubMedCrossRef
38.
Ramage G, Saville SP, Wickes BL, López-Ribot JL (2002) Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 68:5459–5463PubMedCrossRef
39.
LaFleur MD, Kumamoto CA, Lewis K (2006) Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 50:3839–3846PubMedCrossRef
40.
Nett JE, Sanchez H, Cain MT, Andes DR (2010) Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J Infect Dis 202:171–175PubMedCrossRef
41.
Ramage G, Saville SP, Thomas DP, López-Ribot JL (2005) Candida biofilms: an update. Eukaryotic Cell 4:633–638PubMedCrossRef
42.
Ramage G, Wickes BL, López-Ribot JL (2001) Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab 20:42–44PubMed
43.
LaFleur MD, Qi Q, Lewis K (2010) Patients with long-term oral carriage harbor high-persister mutants of candida albicans. Antimicrob Agents Chemother 54(1):39–44PubMedCrossRef
44.
Venkatesh M, Rong L, Raad I, Versalovic J (2009) Novel synergistic antibiofilm combinations for salvage of infected catheters. J Med Microbiol 58(7):936–944PubMedCrossRef
45.
Mermel LA, Farr BM, Sherertz RJ et al (2001) Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 32:1249–1272PubMedCrossRef
46.
Ozdemir H, Karbuz A, Ciftci E et al (2011) Successful treatment of central venous catheter infection due to Candida lipolytica by caspofungin-lock therapy. Mycoses 54:e647–e649PubMedCrossRef
47.
Blackwood RA, Klein KC, Micel LN et al (2001) Ethanol locks therapy for resolution of fungal catheter infections. J Pediatr Infect Dis 30:1105–1107CrossRef
48.
Castagnola E, Marazzi MG, Tacchella A, Giacchino R (2005) Broviac catheter-related candidemia. J Pediatr Infect Dis 24:747CrossRef
49.
Klotz SA, Chasin BS, Powell B et al (2007) Polymicrobial bloodstram infections involving Canida species: analysis of patients and review of the literature. Diagn Microbiol Infect Dis 49:401–406CrossRef
50.
Harriott MM, Noverr MC (2009) Candida albicans and Staphylococcus aureus form polymicrobial biofilms: effects on antimicrobial resistance. Antimicrob Agents Chemother 53(9):3914–3922PubMedCrossRef
51.
Ku TS, Palanisamy SKA, Lee SA (2010) Susceptibility of Candida albicans biofilms to azithromycin, tigecycline, and vancomycin and the interaction between tigecycline and antifungals. Int J Antimicorb Agents 36:441–446CrossRef
52.
Miceli MH, Bernardo SM, Ku TS et al (2012) In vitro analysis of the effects of heparin and parabens on Candida albicans biofilms and planktonic cells. Antimicrob Agents Chemother 56:148–153PubMedCrossRef
53.
Miceli MH, Bernardo SM, Lee SA (2009) In vitro analyses of the combination of high-dose doxycyline and antifungal agents against Candida albicans biofilms. Int J Antimicrob Agents 34:326–332PubMedCrossRef
54.
Sherertz RJ, Boger MS, Collins CA et al (2006) Comparative in vitro efficacies of various catheter lock solutions. Antibicrob Agents Chemother 50:1865–1868CrossRef
55.
Fourneret-Vivier A, Lebeau B, Mallaret MR et al (2006) Hospital-wide prospective mandatory surveillance of invasive aspergillosis in a French teaching hospital (2000–2002). J Hosp Infect 62:22–28PubMedCrossRef
56.
Cornillet A, Camus C, Nimubona S et al (2006) Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 43:577–584PubMedCrossRef
57.
Pagano L, Caira M, Candoni A et al (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91:1068–1075PubMed
58.
Lass-Flörl C, Griff K, Mayr A et al (2005) Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 131:201–207PubMedCrossRef
59.
Marr KA, Carter RA, Crippa F et al (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909–917PubMedCrossRef
60.
Flemming RV, Walsh TJ, Anaissie EJ (2002) Emerging and less common fungal pathogens. Infect Dis Clin N Am 16:915–933CrossRef
61.
Iwen PC, Rupp ME, Langnas AN et al (1998) Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis 26:1092–1097PubMedCrossRef
62.
Verweij PE, Melado E, Melcher WJ (2007) Multiple-Triazole-Resistant Aspergillosis. N Engl J Med 356:1481–1483PubMedCrossRef
63.
Howard SJ, Cesar D, Anderson MJ et al (2009) Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 15:1068–1076PubMedCrossRef
64.
Snelders E, Huis In’t Veld RA, Rijs AJ, Kema GH et al (2009) Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 75:4053–4057PubMedCrossRef
65.
Mayr A, Lass-Flörl C (2011) Epidemiology and antifungal resistance in invasive aspergillosis according to primary disease – review of the literature. Eur J Med Res 16:153–157PubMedCrossRef
66.
Van der Linden JW, Snelders E, Kampinga GA et al (2011) Clinical implications of azole resistance in Aspergillus fumigates, The Netherlands, 2007–2009. Emerg Infect Dis 17:1846–1854CrossRef
67.
Verweij PE, Howard S, Melchers WJG et al (2009) Azole-resistance in aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 12:141–144PubMedCrossRef
68.
Snelders E, Van der Lee HA, Kuijpers J et al (2008) Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 5:e219PubMedCrossRef
69.
Vandeputte P, Ferrari S, Coste AT (2012) Antifungal resistance and new strategies to control fungal infections. Int J Microbiol 2012:713687PubMed
70.
Vanden Bossche H, Marichal P, Odds FC (1994) Molecular mechanisms of drug resistance in fungi. Trends Microbiol 2(10):393–400CrossRef
71.
Peman J, Canton E, Espinel-Ingroff A (2009) Antifungal drug resistance mechanisms. Expert Rev Anti Infect Ther 7:453–460PubMedCrossRef
72.
Sabatelli F, Patel R, Mann PA et al (2006) In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 50:2009–2015PubMedCrossRef
73.
Powderly W, Kobayashi GS, Herzig GP, Medoff G (1988) Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 84(5):826–832PubMedCrossRef
74.
Anaissie E, Karyotakis NC, Hachem R et al (1994) Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis 170(2):384–389PubMedCrossRef
75.
Ellis D (2002) Amphotericin B: spectrum and resistance. J Antimicrob Chemother 49(Suppl 1):7–10PubMedCrossRef
76.
White T, Marr K, Bowden R (1998) Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11(2):382–402PubMed
77.
Perea S, Patterson T (o J) Antifungal resistance in pathogenic fungi. Clin Infect
78.
Du W, Coaker M, Sobel JD, Akins RA (2004) Shuttle vectors for Candida albicans: control of plasmid copy number and elevated expression of cloned genes. Curr Genet 45:390–398PubMedCrossRef
79.
Kelly SL, Lamb DC, Kelly DE (1999) Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fuconazole resistance by preventing binding to haem. FEMS Microbiol Lett 180(2):171–175PubMed
80.
Kelly SL, Lamb DC, Loeffler J et al (1999) The G464S amino acid substitution in Candida albicans sterol 14alpha-demethylase causes fuconazole resistance in the clinic through reduced affinity. Biochem Biophys Res Commun 262:174–179PubMedCrossRef
81.
Lamb DC, Kelly DE, White TC, Kelly SL (2000) The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance through reduced affinity. Antimicrob Agents Chemother 44:63–67PubMedCrossRef
82.
Chamilos G, Kontoyiannis DP (2005) Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat 8:344–345PubMedCrossRef
83.
84.
Kartsonis N, Nielsen J, Douglas CM (2003) Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat 6:197–218PubMedCrossRef
85.
Arikan S, Paetznick V, Rex JH (2002) Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 46:3084PubMedCrossRef
86.
Pfaller MA, Marco F, Messer SA, Jones RN (1998) In vitro activity of two echinocandin derivatives, LY303366, and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 30:251PubMedCrossRef
87.
Ha YS, Covert SF, Momany M (2006) FsFKS1, the 1,3-beta-glucan synthase from the caspofungin-resistant fungus Fusarium solani. Eukaryot Cell 5:1036PubMedCrossRef
88.
Cheung C, Guo Y, Gialanella P, Feldmesser M (2006) Development of candidemia on caspofungin therapy: a case report. Infection 34:345–348PubMedCrossRef
89.
Espinel-Ingroff A (2008) Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoam Micol 25(2):101–106PubMedCrossRef
90.
Perlin DS (2007) Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 10:121–130PubMedCrossRef
91.
Pfaller MA, Diekeman DJ, Gibbs DL et al (2010) Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 1366–1377
92.
Sinkó J, Bryan J (2012) Latest trends in fungal epidemiology inform treatment choices and stewardship initiatives. Future Med Ltd 7(10):1141–1146
93.
Hussain A (2012) Species distribution and anti-fungal susceptibility of Candida spp at the Heart of England Foundation Trust, United Kingdom. Presentet at: 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). London, UK, 31.03.–03.04.2012 (Poster 749)
94.
Kontoyiannis DP, Lewis RE, Osherov N et al (2003) Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 51:313–316PubMedCrossRef
95.
Steinbach WJ, Schell WA, Blankenship JR et al (2004) In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother 48:1664–1669PubMedCrossRef
96.
Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537–549PubMedCrossRef
97.
Lamoth F, Juvvadi PR, Gehrke C, Steinbach WJ (2012) In vitro activity of Calcineurin and heat-shock protein 90 (Hsp90) inhibitors against Aspergillus fumigatus Azole- and Echinocandin-resistant strains. Antimicrob Agents Chemother: doi: 10.1128/AAC.01857-12
98.
Leventakos K, Lewis RE, Kontoyiannis DP (2010) Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis 50:405–415PubMedCrossRef
99.
Ruhnke M, Rickerts V, Cornely OA et al (2011) Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 54:279–310PubMedCrossRef
100.
Metadaten
Titel
Aktuelles aus der Mykologie
Zunehmende Resistenzentwicklung von Hefe- und Schimmelpilzen
verfasst von
Dr. B. Risslegger
Univ.-Prof. Dr. C. Lass-Flörl
Publikationsdatum
01.04.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinisches Magazin / Ausgabe 2/2013
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI
https://doi.org/10.1007/s00740-013-0089-4

Weitere Artikel der Ausgabe 2/2013

Vom Hohelied zum Klagelied

  • Editorial

Krankheit in der Tabuzone

  • Aktuell

Plastizität der WNT-Signalwegaktivität im Kolonkarzinom

  • Originalarbeit

Fehler ? nie ganz vermeidbar

  • Originalarbeit

Revival der extrakorporalen Lungenersatzverfahren

  • Originalarbeit

Blutungsepisoden erfassen

  • Originalarbeit